. 2018 Jun 6;37(9):1653–1659. doi: 10.1007/s10096-018-3295-6

Table 2.

Comparative in vitro activity of ceftobiprole against 650 CoNS from bacteraemias

Organism (n)	Antimicrobial agent	MIC determination			EUCAST MIC interpretation
Organism (n)	Antimicrobial agent	MIC₅₀ (mg/L)	MIC₉₀ (mg/L)	MIC range (mg/L)	Percentage susceptible	Percentage resistant
All (650)	Ceftobiprole	1	2	0.015–4	100^a	0.0^a
	Oxacillin	16	> 128	≤ 0.03–> 128	27.5	72.5
	Ciprofloxacin	2	64	0.06–> 128	49.5	50.5
	Clindamycin	0.125	> 128	≤ 0.03–> 128	74.9	25.1
	Erythromycin	64	> 128	0.125–> 128	31.8	68.2
	Teicoplanin	4	8	0.25–> 16	79.1	20.9
	Vancomycin	2	4	0.5–8	99.8	0.2
S. capitis (47)	Ceftobiprole	0.125	1	0.015–2	100^a	0.0^a
	Oxacillin	0.25	> 128	0.06–> 128	53.2	46.8
	Ciprofloxacin	0.25	4	0.125–8	89.4	10.6
	Clindamycin	0.125	0.25	0.06–> 128	95.7	4.3
	Erythromycin	0.5	> 128	0.125–> 128	70.2	29.8
	Teicoplanin	1	8	0.5–> 16	89.4	10.6
	Vancomycin	2	2	1–8	97.9	2.1
S. epidermidis (411)	Ceftobiprole	1	2	0.06–4	100^a	0.0^a
	Oxacillin	8	128	≤ 0.03–> 128	24.6	75.4
	Ciprofloxacin	4	64	0.125–128	40.4	59.6
	Clindamycin	0.125	> 128	0.06–> 128	68.6	29.0
	Erythromycin	64	> 128	0.125–> 128	28.7	71.3
	Teicoplanin	4	8	0.5–16	73.2	26.8
	Vancomycin	2	4	1–4	100	0.0
Oxacillin-susceptible S. epidermidis (101)	Ceftobiprole	0.25	0.25	0.06–0.25	100^a	0.0^a
	Ciprofloxacin	0.25	8	0.125–128	88.1	11.9
	Clindamycin	0.125	0.125	0.06–> 128	92.1	7.9
	Erythromycin	0.5	> 128	0.125–> 128	52.5	47.5
	Teicoplanin	4	8	0.5–16	88.1	11.9
	Vancomycin	2	2	1–4	100	0.0
Oxacillin-resistant S. epidermidis (310)	Ceftobiprole	1	2	0.125–4	100^a	0.0^a
	Ciprofloxacin	8	64	0.125–128	24.8	75.2
	Clindamycin	0.125	> 128	0.06–> 128	61.0	35.8
	Erythromycin	> 128	> 128	0.125–> 128	21.0	79.0
	Teicoplanin	4	8	1–16	68.4	31.6
	Vancomycin	2	4	1–4	100	0.0
S. haemolyticus (64)	Ceftobiprole	4	4	0.125–4	100^a	0.0^a
	Oxacillin	> 128	> 128	0.125–> 128	3.1	96.9
	Ciprofloxacin	16	128	0.125–> 128	23.4	76.6
	Clindamycin	0.125	> 128	0.06–> 128	73.4	26.6
	Erythromycin	> 128	> 128	0.25–> 128	3.1	96.9
	Teicoplanin	4	8	1–> 16	78.1	21.9
	Vancomycin	2	4	1–4	100	0.0
S. hominis (82)	Ceftobiprole	1	2	0.06–4	100^a	0.0^a
	Oxacillin	8	128	0.06–> 128	35.4	64.6
	Ciprofloxacin	0.25	64	0.06–> 128	69.5	30.5
	Clindamycin	0.125	> 128	0.06–> 128	85.4	13.4
	Erythromycin	> 128	> 128	0.25–> 128	24.4	75.6
	Teicoplanin	0.5	4	0.25–8	91.5	8.5
	Vancomycin	1	2	0.5–4	100	0.0
S. lugdunensis (10)	Ceftobiprole	0.5	0.5	0.25–2	100^a	0.0^a
	Oxacillin	0.5	0.5	0.25–128	90.0	10.0
	Ciprofloxacin	0.25	0.25	0.125–2	90.0	10.0
	Clindamycin	0.06	0.125	0.06–0.125	100	0.0
	Erythromycin	0.125	0.25	0.125–> 128	90.0	10.0
	Teicoplanin	1	1	1–1	100	0.0
	Vancomycin	1	1	1–2	100	0.0
S. warneri (20)	Ceftobiprole	0.5	1	0.125–2	100^a	0.0^a
	Oxacillin	64	> 128	0.125–> 128	30.0	70.0
	Ciprofloxacin	0.5	0.5	0.25–64	95.0	5.0
	Clindamycin	0.06	0.125	0.06–> 128	95.0	5.0
	Erythromycin	0.25	> 128	0.125–> 128	70.0	30.0
	Teicoplanin	2	4	1–4	100	0.0
	Vancomycin	2	2	1–4	100	0.0
Other species (16)^b	Ceftobiprole	0.5	2	0.06–4	100^a	0.0^a
	Oxacillin	0.5	> 128	≤ 0.03–> 128	43.8	56.2
	Ciprofloxacin	0.25	4	0.125–8	87.5	12.5
	Clindamycin	0.125	0.5	≤ 0.03–> 128	87.5	6.3
	Erythromycin	0.25	> 128	0.125–> 128	68.8	31.3
	Teicoplanin	2	4	0.5–4	100	0.0
	Vancomycin	2	2	1–2	100	0.0

^aThe non-species-specific PK/PD breakpoint was used to determine ceftobiprole resistance

^bOrganisms included Staphylococcus cohnii (1), Staphylococcus pasteuri (3), Staphylococcus pettenkoferi (6), Staphylococcus saprophyticus (1), Staphylococcus simulans (4) and unspeciated Staphylococcus (1)

CoNS coagulase-negative staphylococci, EUCAST the European Committee on Antimicrobial Susceptibility Testing, MIC minimum inhibitory concentration